Submissions

Online Submissions

Already have a Username/Password for Pharmaceutical and Biological Evaluations?
Go to Login

Need a Username/Password?
Go to Registration

Registration and login are required to submit items online and to check the status of current submissions.

 

Author Guidelines

  • Guide for Authors

    General

    Pharmaceutical and Biological Evaluations is self-sponsored and aims to set up an academic communicating platform for Indian and scientists all over the world. The Journal invites concise reports of original research in all areas of Pharmacy both experimental and clinical, including modern, traditional and epidemiological studies including Biotechnology, from any part of the world. Review articles based primarily on authors’ own research on internationally important topics will be accepted. Short communications and letters to the editor are also welcome. Authors are requested to submit a covering letter indicating that their manuscript represents original unpublished material that has not been and will not be published elsewhere (if accepted). This restriction does not apply to results published as abstracts of communications, letters to the editor or as preliminary reports. The manuscripts must be submitted in Microsoft word (.doc, .docx) only. By submitting a manuscript the authors warrant that they have obtained permission to use any copyrighted or previously published materials.

    MANUSCRIPT CONTENTS

    Manuscript

    The manuscript should be submitted online through our website and the text should be double spaced 12 pt Times New roman and have wide margins. The manuscript should be arranged in the following order:

    1) Title Page, 2) Keywords, 3) Abstract, 4) Corresponding author, 5) Introduction, 6) Materials and Methods, 7) Results, 8) Discussion, 9) Acknowledgments, 10) References, 11) Tables, 12) Figure Legends and 13) Figures. Please indicate the page of your manuscripts to facilitate reviewing.

    Review articles

    Review articles are summaries of excellent scientific research articles which deal with specific research areas of within the scope of the Pharmaceutical and Biological Evaluations. Review articles should be approximately 3000 words.

    Short communications

    Short communications not exceeding two printed pages, including title, author affiliations, references and one figure or table, are acceptable for rapid publication if requested by the authors.

    Letters to the editor

    Criticisms or comments of less than 500 words and five references are welcome. Preference is given to letters related to articles published in the Pharmaceutical and Biological Evaluations.

    Title page

    The title page should contain, on separate lines, the title of the manuscript, a running title of no more than 40 letters, the name(s) and affiliation(s) of the author(s), and the mailing address, telephone and fax numbers, and Email address of the corresponding author. The title must be informative, specific, and concise. Serialization of articles into parts is not permitted; such articles may be submitted independently with self-sufficient titles.

    Authors

    All authors should have participated sufficiently in the work to take public responsibility for the content. Written approval signed by all authors should be presented with the manuscript. 12 pt Times New Roman centered, bold – author and all co-authors names in one line. The corresponding author should include an asterisk*. The affiliations are in 12 pt Times New roman centered – giving each authors’ affiliation (i.e. Department/Organization/Address/Place/Country/email). Followed by single line spacing. Author for Correspondence: 10pt Times New roman centered – giving a valid e-mail of the corresponding (main) author is a must. It should be indicated as* followed by two line spacing.

    Abstract

    The Abstract of the manuscript should not exceed 350 words and must be structured into separate sections: Objective, the context and purpose of the study; Methods, how the study was performed and statistical tests used; Results, the main findings; Conclusions, brief summary and potential implications. Please minimize the use of abbreviations and do not cite references in the abstract. 12 pt Times New roman, full justification Normal – maximum 350 words

    Keywords

    Provide 3–10 key words or phrases for indexing purposes, using terms from the latest US National Library of Medicine’s Medical Subject Headings (MeSH) browser list at http://www.nlm.nih.gov/mesh/meshhome.html. If appropriate MeSH terms are not available, other suitable terms may be used.

    Text

    Major headings (ABSTRACT, KEYWORDS, INTRODUCTION, MATERIALS AND METHODS, RESULTS, DISCUSSION, ACKNOWLEDGEMENTS, REFERENCES) in upper case left-justified, 12 pt bold, Intermediate headings should be in italics, sentence case, left justified, 12 pt.

    The text should include the following sections.

    Introduction: The Introduction summarizes the rationale, provides a concise research background (not an exhaustive review) and states in one sentence the objective of the study. Do not include any results or the conclusions of the study.

    Materials and Methods: The Materials and Methods provide technical information about the study. Do not describe methodological details that have been published previously. Specifications (including the manufacturer, city, and the country) should be given for the main drugs, chemicals, and instruments. Indicate the statistical methods used and identify statistical significance using superscripts (a and b) following the data (aP < 0.05, bP < 0.01).

    Results: The Results are the findings, using SI units. In a sample, the number of effective digits is determined by the variation within the sample, that is, one-third of the standard deviation. Digits may be separated into groups of three by a small space.

    Discussion: The Discussion deals with the interpretation of the results and their comparison with those of other studies. Do not repeat the results, do not review the literature, do not repeat textbook knowledge and do not cite references that do not have a close relationship with the present results. End with a brief conclusion linking back to the aim of the study.

    Abbreviations

    The use of abbreviations, except for units of measure, is discouraged. At the first appearance in the abstract and the text, abbreviations should be preceded by words for which they stand.

    Tables

    Tables must be concise and cited consecutively using Arabic numerals in the text (Table 1, Table 2, etc.). Each table should be typed on a separate sheet, have a short, one-line title in bold text. Tables should be as small as possible. The title of the table should clearly indicate the nature of the contents and sufficient details should be included in the footnote to facilitate interpretation without reference to the text. Symbols and abbreviations are defined immediately below the table, followed by essential descriptive material as briefly as possible, all in double-spaced text.

    Figures

    Figures (photographs, drawings, diagrams and charts) should be clear, easily legible and cited consecutively using Arabic numerals in the text (Figure 1, Figure 2…etc.). The goal is for figures to be comprehensible to readers in other or related disciplines, and to assist their understanding of the paper. Unnecessary figures and parts (panels) of figures should be avoided: data presented in small tables or histograms, for instance, can generally be stated briefly in the text instead. Avoid unnecessary complexity, colouring and excessive detail. Please supply figures 1.5 to 2 times the size at which they will be finally reproduced. For line work, submit black-ink drawings of professional quality. Micrographs or other glossy photographs must be of the highest quality. Use standard symbols: ○, ●, ×, □, ■, △, ▲. Freehand or typewritten lettering is unacceptable. If a figure comprises more than one glossy photograph, these should be marked A, B, C…etc. Figure legends should be marked clearly with their correspond letters. Legends should contain sufficient detail to permit figure interpretation without reference to the text. Scale markers should be indicated in the photographs. Color plates are also welcome. The choice of cover art illustration will be made by the Editor.

    Lettering in figures should be in lower-case type, with the first letter capitalized and no full stop. Units should have a single space between the number and the unit, and follow SI nomenclature or the nomenclature common to a particular field. Thousands should be separated by commas (1,000). Unusual units or abbreviations are defined in the legend. The illustration or figure must be prepared at a minimum of 350 dpi at the final publication size. Lower resolution will result in pixilation and poor quality images. These should be submitted as JPEG, TIFF or PPT files.

    Table and Figure captions

    Figure and table captions should be included at the end of the manuscript. Figure captions/legends should include a statement at the end of each caption/legends about reproduction size (e.g. at full page width, at column width). They should be double spaced and typed in the journal format. Explanations should be brief and authors should keep in mind that captions/legends will be placed below figures.

    EXAMPLES OF REFERENCES – VANCOUVER STYLE

    (from Uniform Requirements for Manuscripts, www.icmje.org)

    Articles in Journals

    1. Standard journal article

    List the first six authors followed by et al. (Note: NLM now lists up through 25 authors; if there are more than 25 authors, NLM lists the first 24, then the last author, then et al.)

    Halpern SD, Ubel PA, Caplan AL. Solid-organ transplantation in HIV-infected patients. N Engl J Med. 2002;347(7):284-7.

    As an option, if a journal carries continuous pagination throughout a volume (as many medical journals do) the month and issue number may be omitted.
    (Note: For consistency, the option is used throughout the examples in Uniform Requirements. NLM does not use the option.)

    Halpern SD, Ubel PA, Caplan AL. Solid-organ transplantation in HIV-infected patients. N Engl J Med. 2002;347:284-7.

    More than six authors: Gillespie NC, Lewis RJ, Pearn JH, Bourke ATC, Holmes MJ, Bourke JB, et al. Ciguatera in Australia: occurrence, clinical features, pathophysiology and management. Med J Aust. 1986;145:584-90.

    2. Organization as author

    The Cardiac Society of Australia and New Zealand. Clinical exercise stress testing. Safety and performance guidelines. Med J Aust. 1996;164:282-4.

    3. No author given

    Cancer in South Africa [editorial]. S Afr Med J. 1994;84:15.

    4. Article not in English

    (Note: NLM translates the title to English, encloses the translation in square brackets, and adds an abbreviated language designator.) Ryder TE, Haukeland EA, Solhaug JH. Bilateral infrapatellar seneruptur hostidligere frisk kvinne. Tidsskr Nor Laegeforen. 1996;116:41-2.

    5. Volume with supplement

    Geraud G, Spierings EL, Keywood C. Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan. Headache. 2002;42 Suppl 2:S93-9.

    6. Issue with supplement

    Payne DK, Sullivan MD, Massie MJ. Women’s psychological reactions to breast cancer. Semin Oncol. 1996;23(1 Suppl 2):89-97.

    7. Volume with part

    Ozben T, Nacitarhan S, Tuncer N. Plasma and urine sialic acid in non-insulin dependent diabetes mellitus. Ann Clin Biochem. 1995;32(Pt 3):303-6.

    8. Issue with part

    Poole GH, Mills SM. One hundred consecutive cases of flap lacerations of the leg in ageing patients. N Z Med J. 1994;107(986 Pt 1):377-8.

    9. Issue with no volume

    Turan I, Wredmark T, Fellander-Tsai L. Arthroscopic ankle arthrodesis in rheumatoid arthritis. Clin Orthop. 1995;(320):110-4.

    10. No issue or volume

    Browell DA, Lennard TW. Immuno-logic status of the cancer patient and the effects of blood transfusion on antitumor responses. Curr Opin Gen Surg. 1993:325-33.

    11. Pagination in Roman numerals

    Fisher GA, Sikic BI. Drug resistance in clinical oncology and hematology. Introduction. Hematol Oncol Clin North Am. 1995 Apr;9(2):xi-xii.

    12. Type of article indicated as needed

    Enzensberger W, Fischer PA. Metronome in Parkinson’s disease [letter]. Lancet. 1996;347:1337. Clement J, De Bock R. Hematological complications of hantavirus nephro-pathy (HVN) [abstract]. Kidney Int. 1992;42:1285.

    13. Article containing retraction

    Garey CE, Schwarzman AL, Rise ML, Seyfried TN. Ceruloplasmin gene defect associated with epilepsy in EL mice [retraction of Garey CE, Schwarzman AL, Rise ML, Seyfried TN. In: Nat Genet. 1994;6:426-31]. Nat Genet. 1995;11:104.

    14. Article retracted

    Liou GI, Wang M, Matragoon S. Precocious IRBP gene expression during mouse development [retracted in Invest Ophthalmol Vis Sci. 1994;35:3127]. Invest Ophthalmol Vis Sci. 1994;35:1083-8.

    15. Article with published erratum

    Hamlin JA, Kahn AM. Herniography in symptomatic patients following inguinal hernia repair [published erratum appears in West J Med. 1995;162:278]. West J Med. 1995;162:28-31. Books and Other Monographs (Note: Previous Vancouver style incorrectly had a comma rather than a semicolon between the publisher and the date.)

    16. Personal author(s)

    Ringsven MK, Bond D. Gerontology and leadership skills for nurses. 2nd ed. Albany (NY): Delmar Publishers; 1996.

    17. Editor(s), compiler(s) as author

    Norman IJ, Redfern SJ, editors. Mental health care for elderly people. New York: Churchill Livingstone; 1996.

    18. Organization as author and publisher

    Institute of Medicine (US). Looking at the future of the Medicaid program. Washington: The Institute; 1992.

    19. Chapter in a book

    (Note: Previous Vancouver style had a colon rather than a p before pagination.) Phillips SJ, Whisnant JP. Hypertension and stroke. In: Laragh JH, Brenner BM, editors. Hyperten-sion: pathophysiology, diagnosis, and management. 2nd ed. New York: Raven Press; 1995: 465-478.

    20. Conference proceedings

    Kimura J, Shibasaki H, editors. Recent advances in clinical neuro-physiology. Proceedings of the 10th International Congress of EMG and Clinical Neurophysiology; 1995 Oct 15-19; Kyoto, Japan. Amsterdam: Elsevier; 1996.

    21. Conference paper

    Bengtsson S, Solheim BG. Enforce-ment of data protection, privacy and security in medical informatics. In: Lun KC, Degoulet P, Piemme TE, Rienhoff O, editors. MEDINFO 92. Procee-dings of the 7th World Congress on Medical Infor-matics; 1992 Sep 6-10; Geneva, Switzerland. Amsterdam: North-Holland; 1992: 1561-5.

    22. Scientific or technical report

    Issued by funding/sponsoring agency: Smith P, Golladay K. Payment for durable medical equipment billed during skilled nursing facility stays. Final report. Dallas (TX): Dept. of Health and Human Services (US), Office of Evaluation and Inspections; 1994 Oct. Report No.: HHSIGOEI69200860. Issued by performing agency: Field MJ, Tranquada RE, Feasley JC, editors. Health services research: work force and educational issues. Washington: National Academy Press; 1995. Contract No.: AHCPR282942008. Sponsored by the Agency for Health Care Policy and Research.

    23. Dissertation

    Kaplan SJ. Post-hospital home health care: the elderly’s access and utilization [dissertation]. St. Louis (MO): Washington Univ.; 1995.

    24. Patent

    Larsen CE, Trip R, Johnson CR, in-ventors; Novoste Corporation, assignee. Methods for procedures re-lated to the electrophysiology of the heart. US patent 5,529,067. 1995 Jun 25. Other Published Material

    25. Newspaper article

    Lee G. Hospitalizations tied to ozone pollution: study estimates 50,000 admissions annually. The Washington Post 1996 Jun 21;Sect. A:3 (col. 5).

    26. Audiovisual material

    HIV+/AIDS: the facts and the future [videocassette]. St. Louis (MO): Mosby-Year Book; 1995.
    27. Legal material Public law: Preventive Health Amendments of 1993, Pub. L. No. 103-183, 107 Stat. 2226 (Dec. 14, 1993).

    Unenacted bill: Medical Records Confidentiality Act of 1995, S. 1360, 104th Cong., 1st Sess. (1995).

    Code of Federal Regulations:

    Informed Consent, 42 C.F.R. Sect. 441.257 (1995). Hearing: Increased Drug Abuse: the Impact on the Nation’s Emergency Rooms: Hearings Before the Subcomm. on Human Resources and Intergovernmental Relations of the House Comm. on Government Operations, 103rd Cong., 1st Sess. (May 26, 1993).

    28. Map

    North Carolina. Tuberculosis rates per 100,000 population, 1990 [demo-graphic map]. Raleigh: North Carolina Dept. of Environment, Health, and Natural Resources, Div. of Epidemio-logy; 1991.

    29. Book of the Bible

    The Holy Bible. King James version. Grand Rapids (MI): Zondervan Publishing House; 1995. Ruth 3:1-18.

    30. Dictionary and similar references

    Stedman’s medical dictionary. 26th ed. Baltimore: Williams & Wilkins; 1995. Apraxia; p. 119-20.

    31. Classical material

    The Winter’s Tale: act 5, scene 1, lines 13-16. The complete works of William Shakespeare. London: Rex; 1973. Unpublished Material

    32. In press

    (Note: NLM prefers “forthcoming” because not all items will be printed.) Leshner AI. Molecular mechanisms of cocaine addiction. N Engl J Med. In press 1996.

    Electronic Material

    33. Journal article in electronic format

    Schimdt D, Lynch, J. Evaluation of the reproducibility of parallel artificial membrane permeation assays (PAMPA). Millipore Corporation; USA [Serial online] 2002 [cited in 2002]. Available from:http://www.millipore.com/techpublications/tech1/ANI728EN00

    Peer review process     

    Pharmaceutical and Biological Evaluations considers manuscripts for review with understanding that the manuscript is submitted to this journal only at this time and has not been published anywhere, submitted simultaneously or already accepted for publication anywhere. After submission, manuscripts are reviewed thoroughly by editors. The section editor proceeds for further review process to the reviewers if satisfies or sends for revision or reject if the manuscript is not suitable for the journal. Those manuscripts which are found suitable for publication in Pharmaceutical and Biological Evaluations are sent to two or more reviewers. During the submission process, corresponding author is requested to suggest two qualified reviewers which is optional. The reviewers should not be affiliated to the same organization the authors belong to. The section editor takes final decision (acceptance/rejection/revisions) basing on the reviewers comments. Corresponding author is requested to submit revised manuscript as per reviewer’s comments if suggestions/comments are sent. Revised manuscript is accepted if reviewers and editor are satisfied. Final proof of the manuscript is sent to the corresponding author and expected to return corrected proof within 48 hours through email. After that time corrections may not be accepted. Then the manuscripts are processed for publication.

    Editorial Policy

    The editorial management and peer review process is conducted by the editorial team members. Editorial manager’s responsibility is to assign manuscripts to editors/section editors of the specific filed. Pharmaceutical and Biological Evaluations is committed to process all the submitted articles strictly through peer review process and to prevent any conflicts of interests between editorial and review process. Section editor’s duty is to review the manuscript as per journal’s scope and conduct peer review process by assigning two or three reviewers. Section editors hold full authority to accept/reject a submission and only accept a paper when fulfills the journal’s standards and also can reject if consider not suitable for this journal.

    Authors should prepare manuscripts according to the instructions given before submission. Manuscripts may be returned for revisions or rejected if it is not prepared according to the instructions. Pharmaceutical and Biological Evaluations reserves the right to make changes and corrections necessary in the manuscript which is accepted for publication.

    Responsibilities of Editors

    Editors have many roles towards the authors and reviewers of the journal.

    • To providing guidelines to author for submission of manuscript.
    • To provide clear statement of the journal policies to the author.
    • To treat all author with fairness, transparency, honesty.
    • To protect the confidentiality of every authors work and with the reviewers.
    • To establish and define policies on conflict of interest for all involved in publication process including editorial staff, editorial assistants, and author’s reviewers.
    • To conduct a systematic and rapid peer-review process.
    • To assign manuscripts to reviewers of the specific subject area and expertise and also to inform the reviewers to maintain confidentiality.
    • To conduct and complete the review process in time by communication with to the reviewers regularly.
    • To make decision in a responsive speed and communicating them in a transparent manner.
    • To regularly review and implement policies for handling ethical issues and allegations or finding of misconduct by authors and anyone involved in peer review process.
    • To develop system, in cooperation with publisher to ensure timely publication of manuscripts.

    Publication Ethics

    The editors, reviewers and authors of Pharmaceutical and Biological Evaluations are expected to follow the standards of the journal. It is the responsibility of the corresponding author to obtain the consent of all coauthors before submitting a manuscript for publication. If any change in authorship is required after submission, the corresponding author must mail a signed letter with new order of authors to the Managing Editor with confirmation that the new order of authors are notified to all coauthors.

    Responsibilities of Authors

    Originality: Author(s) must ensure the originality and authenticity of all data given in the work. Author(s) must make sure that the listed authors of the work are the only contributors in the work. The authors must admit that they have unveiled all and any actual or potential conflicts of interest with their work or partial benefits associated with it.

    Disclosures: Authors have a duty to disclose necessary information related to the work at the time of submission. This includes disclosure about the novelty of the content, author’s actual contribution to the study, sources of funding for the study, and financial and conflict of interest disclosures.

    Conflict of interest

    All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding.

    Acknowledgements

    Any acknowledgements should appear first at the end of your article prior to your Declaration of Conflicting Interests (if applicable), any notes and your References.

    All contributors who do not meet the criteria for authorship should be listed in an ‘Acknowledgements’ section. Examples of those who might be acknowledged include a person who provided purely technical help, writing assistance, or a department chair who provided only general support. Authors should disclose whether they had any writing assistance and identify the entity that paid for this assistance.

    Funding Acknowledgement

    To comply with the guidance for Research Funders, Authors and Publishers, Pharmaceutical and Biological Evaluations additionally requires all Authors to acknowledge their funding in a consistent fashion under a separate heading.

    Copyright

    The submission of a manuscript by authors implies that they automatically agree to assign exclusive copyright to the Pharmaceutical and Biological Evaluations if the manuscript is accepted for publication. The work should not be published elsewhere in any form without the written permission of the Pharmaceutical and Biological Evaluations. All rights of the articles published in the Pharmaceutical and Biological Evaluations are reserved. No part of this publication may be reproduced, translated or transmitted in any form or by any means (electronic, mechanical or otherwise) without permission from the Pharmaceutical and Biological Evaluations.

    Please Download Copyright Form here

    Ethics

    Pharmaceutical and Biological Evaluations insists on ethical practices in both human and animal experiments. Evidence for approval by a local Ethics Committee must be supplied by the authors on demand. Animal experimental procedures should be as humane as possible and the details of anaesthetics and analgesics used should be clearly stated. The ethical standards of experiments must be in accordance with the guidelines provided by the CPCSEA (animal) and ICMR (human). The journal will not consider any paper which is ethically unacceptable. A statement on ethics committee permission and ethical practices must be included in all research articles under the ‘Materials and Methods’ section.

    Publication Ethics and Malpractice Statement

    Pharmaceutical and Biological Evaluations is strongly committed to maintain the highest ethical publication standards and also takes all possible actions against any publication malpractices. All submitting author(s) need to ensure that the submitted work is contributed by the authors, is original and is not copied or plagiarized in whole/part from other works.

    At any time, if it is found that a published paper holds any major inaccuracy, plagiarism or misleading statement it will be corrected promptly. After investigation, if found to be illegal/unethical, then that will be retracted and clearly noticeable to readers. The Editorial Board team monitors the publishing ethics of the journal.

    PLAGIARISM

    Authors should note that copying text, tables or illustrations from any source (journal article, book, monographs, thesis, Internet/any electronic media or any other published or unpublished material) and passing it as ones own is considered plagiarism whether or not a reference to the copied portion is given. Listing the source of copied material under ‘References’ does not absolve the authors of plagiarism. If a few lines of text are to be reproduced from any source, ‘the author’ and ‘the source’ must be clearly indicated in the text. The reproduced lines must be in italics and given within quotes. If it is a paragraph it must be slightly indented also. To reproduce large portions of text, permission from the copyright owner(s) must be obtained and submitted to Pharmaceutical and Biological Evaluations. To reproduce tables or illustrations, permission from the copyright owner(s) must be obtained and a copy of the permission letter must be submitted to the journal. The source must be clearly acknowledged below the table or illustration as required by the copyright owner(s).

    Retractions

    Articles may be retracted for scientific or ethical reasons. Articles that contain inaccuracy, plagiarism, illegal/unethical data may be retracted. Retractions may be requested by the article author(s) or by the journal Editor(s), but are ultimately published at the decision of the Editor. When an article is retracted, a notice of Retraction will be published containing information about the original article title, author list, and the reason for the Retraction and will be marked as “Retracted article”.

    Authors’ checklist for Submission

    • Registration and login are required to submit items online and to check the status of current submissions.
    • Manuscript as per Authors
    • Cover Letter
    • Copyright Transfer Form signed by each author.
    • Thoroughly check the reference style as mentioned above.
    • Thoroughly check the article for correct grammar, in particular: spelling of names, affiliations, any symbols, equations, etc.
    • Provide all figures and graphics in 350 Dpi along with legend (If any)
    Fee

    This journal is an Open Access, non-commercial and currently, self-financing. Hence, a nominal cost is being charged to cover the cost of journal hosting, in-house copyediting and pagination and typesetting. The amount that is collected from the authors is reinvested on the journal maintenance and progress the quality of service to our valuable authors.

    The journal does not charge any article processing charges. Authors have to pay publication fee after acceptance of the paper.

    • Publication fee for authors from Indian: 1150 INR
    • Publication fee for authors from outside India: 50 USD

    Pharmaceutical and Biological Evaluations also provides fast track review and publication facility to reduce the decision and publication time. Please send a mail to the editor (editor@onlinepbe.com) to know more about this service.

    Tutorial For Submitting a Manuscript

     

 

Submission Preparation Checklist

As part of the submission process, authors are required to check off their submission's compliance with all of the following items, and submissions may be returned to authors that do not adhere to these guidelines.

  1. The submission has not been previously published, nor is it before another journal for consideration (or an explanation has been provided in Comments to the Editor).
  2. The submission file is in OpenOffice, Microsoft Word, RTF, or WordPerfect document file format.
  3. Where available, URLs for the references have been provided.
  4. The text is single-spaced; uses a 12-point font; employs italics, rather than underlining (except with URL addresses); and all illustrations, figures, and tables are placed within the text at the appropriate points, rather than at the end.
  5. The text adheres to the stylistic and bibliographic requirements outlined in the Author Guidelines, which is found in About the Journal.
  6. If submitting to a peer-reviewed section of the journal, the instructions in Ensuring a Blind Review have been followed.
 

Copyright Notice

The submission of a manuscript by authors implies that they automatically agree to assign exclusive copyright to the Pharmaceutical and Biological Evaluations if the manuscript is accepted for publication. The work should not be published elsewhere in any form without the written permission of the Pharmaceutical and Biological Evaluations. All rights of the articles published in the Pharmaceutical and Biological Evaluations are reserved. No part of this publication may be reproduced, translated or transmitted in any form or by any means (electronic, mechanical or otherwise) without permission from the Pharmaceutical and Biological Evaluations.

Please Download Copyright Form here

Please Download Cover letter here

 

Privacy Statement

The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.

 


Creative Commons License

 

© Copyright 2017 - Pharmaceutical and Biological Evaluations